
  
    
      
        Introduction_NNP
        α-_NN Actinin_NNP is_VBZ an_DT actin-binding_JJ cytoskeletal_NN protein_NN
        present_JJ in_IN a_DT variety_NN of_IN cells_NNS [_NN 1_CD ]_NN and_CC in_IN focal_JJ adhesion_NN
        sites_NNS where_WRB cells_NNS adhere_VB to_TO the_DT substrate_NN [_NN 2_CD ]_NN ._. There_EX is_VBZ
        biochemical_JJ [_NN 3_CD ]_NN and_CC histologic_JJ [_NN 4_CD ]_NN evidence_NN that_IN focal_JJ
        adhesion_NN complexes_NNS ,_, containing_VBG α-actinin_JJ and_CC other_JJ footpad_NN
        material_NN ,_, are_VBP left_VBN behind_IN as_IN a_DT result_NN of_IN normal_JJ movement_NN of_IN
        cells_NNS [_NN 2_CD ]_NN ,_, perhaps_RB at_IN increased_VBN rates_NNS when_WRB neutrophils_NNS
        and_CC monocytes_NNS move_VBP into_IN inflammatory_JJ tissue_NN ._. We_PRP have_VBP shown_VBN
        that_IN α-actinin_JJ is_VBZ abundant_JJ in_IN the_DT bone_NN marrow_NN stroma_NN
        matrix_NN ,_, presumably_RB at_IN focal_JJ adhesion_NN sites_NNS [_NN 5_CD ]_NN ._. We_PRP have_VBP
        also_RB reported_VBN that_IN a_DT 31_CD kDa_NN amino-terminal_JJ α-actinin_JJ
        fragment_NN ,_, which_WDT we_PRP have_VBP named_VBN mactinin_NN ,_, is_VBZ generated_VBN by_IN the_DT
        degradation_NN of_IN extracellular_NN α-actinin_JJ by_IN monocyte-secreted_JJ
        urokinase_NN [_NN 6_CD ]_NN ._. Furthermore_RB ,_, we_PRP have_VBP demonstrated_VBN that_DT
        mactinin_NN is_VBZ present_JJ in_IN inflammation_NN caused_VBN by_IN 
        Pneumocystis_NNP carinii_NN pneumonia_NN ,_, by_IN
        examining_VBG bronchoalveolar_NN lavage_NN fluid_JJ from_IN mice_NNS with_IN
        infection_NN [_NN 6_CD ]_NN ._. It_PRP was_VBD not_RB present_JJ in_IN mice_NNS not_RB challenged_VBN
        with_IN 
        P_NN ._. carinii_NN ,_, suggesting_VBG that_DT
        inflammaton_NN is_VBZ necessary_JJ for_IN mactinin_NN formation_NN ._. We_PRP have_VBP
        also_RB reported_VBN that_DT mactinin_NN promotes_VBZ monocyte_NN /_NN macrophage_NN
        maturation_NN [_NN 7_CD ]_NN ._. For_IN example_NN ,_, α-actinin_JJ fragments_NNS
        significantly_RB increase_VBP lysozyme_NN secretion_NN and_CC
        tartate-resistant_JJ acid_NN phosphatase_NN staining_VBG in_IN peripheral_JJ
        blood_NN monocytes_NNS ._. In_IN contrast_NN ,_, intact_JJ α-actinin_JJ has_VBZ no_DT
        maturation-promoting_JJ activity_NN ._. We_PRP proposed_VBD that_DT mactinin_NN is_VBZ
        present_JJ in_IN the_DT microenvironment_NN at_IN sites_NNS of_IN various_JJ types_NNS
        of_IN inflammation_NN ,_, perhaps_RB owing_VBG to_TO migrating_VBG cell_NN
        populations_NNS ,_, and_CC there_EX it_PRP might_MD contribute_VB to_TO the_DT
        recruitment_NN and_CC maturation_NN of_IN monocytes_NNS ._.
        Monocyte_NNP /_NN macrophage_NN infiltration_NN has_VBZ a_DT key_JJ role_NN in_IN the_DT
        pathogenesis_NNS of_IN chronic_JJ arthritis_NN [_NN 8_CD ]_NN ._. The_DT release_NN of_IN
        pro-inflammatory_JJ cytokines_NNS ,_, chemokines_NNS ,_, growth_NN factors_NNS ,_, and_CC
        enzymes_NNS by_IN the_DT synovial_NN lining_NN macrophages_NNS is_VBZ important_JJ for_IN
        the_DT onset_NN ,_, propagation_NN ,_, and_CC flare_VBP of_IN arthritic_JJ inflammation_NN
        [_NN 9_CD ]_NN ._. The_DT finding_VBG that_IN the_DT number_NN of_IN synovial_NN tissue_NN
        macrophages_NNS is_VBZ correlated_JJ with_IN joint_JJ destruction_NN in_IN
        rheumatoid_NN arthritis_NN is_VBZ evidence_NN of_IN their_PRP$ importance_NN [_NN 9_CD 10_CD
        ]_NN ._. Monocytes_NNP and_CC macrophages_NNS are_VBP believed_VBN to_TO have_VB a_DT
        similar_JJ role_NN in_IN other_JJ chronic_JJ inflammatory_JJ joint_JJ diseases_NNS ,_,
        such_JJ as_IN gout_NN [_NN 11_CD ]_NN and_CC psoriatic_JJ arthropathy_NN [_NN 12_CD ]_NN ._.
        Therefore_RB in_IN this_DT study_NN we_PRP assessed_VBD the_DT effects_NNS of_IN mactinin_NN
        on_IN monocyte_NN chemotaxis_NNS 
        in_IN vitro_NN ._. We_PRP have_VBP also_RB tested_VBN
        synovial_NN fluid_JJ from_IN patients_NNS with_IN various_JJ types_NNS of_IN
        arthritis_NN ,_, including_VBG rheumatoid_NN arthritis_NN ,_, psoriatic_JJ
        arthritis_NN ,_, reactive_JJ arthritis_NN ,_, gout_NN ,_, and_CC ankylosing_VBG
        spondylitis_NNS ,_, for_IN the_DT presence_NN of_IN the_DT monocyte_NN /_NN macrophage_NN
        maturation-promoting_JJ fragment_NN ,_, mactinin_NN ._. We_PRP have_VBP also_RB
        investigated_VBN whether_IN mactinin_NN is_VBZ present_JJ in_IN the_DT
        antigen-induced_JJ arthritis_NN model_NN in_IN rabbits_NNS [_NN 13_CD 14_CD ]_NN ._.
        Macrophages_NNP are_VBP believed_VBN to_TO be_VB important_JJ in_IN this_DT model_NN of_IN
        rheumatoid_NN arthritis_NN [_NN 15_CD 16_CD ]_NN ,_, and_CC both_DT the_DT arthritic_JJ and_CC
        control_VB joint_JJ fluid_NN can_MD be_VB tested_VBN for_IN mactinin_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Source_NN of_IN mactinin_NN
          As_IN described_VBD previously_RB [_NN 6_CD ]_NN ,_, a_DT pGEX_NN 2_CD vector_NN ,_,
          encoding_VBG the_DT actin-binding_JJ domain_NN ,_, residues_NNS 2_CD -_: 269_CD of_IN
          chicken_NN smooth_JJ muscle_NN α-actinin_JJ ,_, fused_JJ with_IN the_DT carboxy_NN
          terminus_JJ of_IN glutathione_NN S-_NNP transferase_NN (_( GST_NNP )_) with_IN an_DT
          engineered_VBN thrombin_NN cleavage_NN site_NN ,_, was_VBD kindly_RB provided_VBN by_IN
          Dr_NNP DR_NNP Critchley_NNP of_IN the_DT University_NNP of_IN Leicester_NNP ,_, UK_NNP ._.
          Fusion_NNP protein_NN was_VBD expressed_VBN in_IN 
          Escherichia_NNP coli_NNS ,_, and_CC the_DT cleavage_NN
          products_NNS of_IN the_DT fusion_NN protein_NN were_VBD purified_JJ by_IN affinity_NN
          chromatography_NN of_IN cell_NN extracts_NNS on_IN immobilized_JJ
          glutathione_NN ._. The_DT fusion_NN protein_NN was_VBD then_RB cleaved_JJ with_IN
          thrombin_NN (_( Calbiochem_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) to_TO yield_VB the_DT
          actin-binding_JJ domain_NN of_IN α-actinin_JJ and_CC the_DT GST_NNP carrier_NN ._.
          The_DT cleavage_NN products_NNS were_VBD then_RB separated_VBN by_IN
          reverse-phase_JJ high-performance_JJ liquid_JJ chromatography_NN on_IN a_DT
          C-_NNP 4_CD column_NN [_NN 6_CD ]_NN ._. SDS-PAGE_NNP demonstrated_VBD that_IN the_DT
          α-actinin_JJ fragment_NN was_VBD more_JJR than_IN 90_CD %_NN of_IN the_DT total_JJ protein_NN
          of_IN pooled_VBN fractions_NNS ,_, with_IN the_DT remaining_VBG 10_CD %_NN being_VBG carrier_NN
          GST_NNP ._. The_DT calculated_VBN molecular_JJ mass_NN of_IN this_DT α-actinin_JJ
          fragment_NN was_VBD 30_CD ,_, 700_CD Da_NNP ._. In_IN this_DT report_NN ,_, both_DT the_DT active_JJ
          product_NN of_IN urokinase_NN degradation_NN of_IN α-actinin_JJ formed_VBN 
          in_IN vivo_NN [_NN 6_CD ]_NN and_CC the_DT active_JJ
          recombinant_JJ actin-binding_JJ domain_NN ,_, which_WDT are_VBP of_IN similar_JJ
          molecular_JJ masses_NNS ,_, will_MD be_VB referred_VBN to_TO as_IN mactinin_NN ._.
          Mactinin_NNP and_CC GST_NNP routinely_RB assay_NN negative_JJ for_IN protein_NN
          endotoxin_NN with_IN a_DT Pyrotell_NNP chromogenic_JJ assay_NN kit_NN ,_, which_WDT
          can_MD detect_VB more_JJR than_IN 0_CD ._. 25_CD endotoxin_NN units_NNS /_NN ml_NN (_( Associates_NNPS
          of_IN Cape_NNP Cod_NNP ,_, Woods_NNP Hole_NNP ,_, MA_NNP )_) ._.
        
        
          Isolation_NNP of_IN peripheral_JJ blood_NN monocytes_NNS
          Mononuclear_NNP cells_NNS were_VBD isolated_VBN from_IN buffy_NN coat_NN
          preparations_NNS of_IN healthy_JJ blood_NN donors_NNS by_IN density_NN gradient_NN
          centrifugation_NN with_IN Histopaque_NNP 1077_CD (_( Sigma_NNP )_) ._.
          Contaminating_NNP red_JJ cells_NNS were_VBD then_RB lysed_JJ in_IN distilled_VBN
          water_NN ,_, and_CC the_DT sample_NN was_VBD applied_VBN to_TO an_DT LS_NNP separation_NN
          column_NN with_IN a_DT magnetic_JJ monocyte_NN isolation_NN kit_NN in_IN
          accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS (_( Miltenyi_NNP
          Biotec_NNP ,_, Auburn_NNP ,_, CA_NNP )_) ._. This_DT negative_JJ selection_NN method_NN
          resulted_VBD in_IN a_DT cell_NN population_NN containing_VBG more_JJR than_IN 90_CD %_NN
          monocytes_NNS as_IN determined_VBN by_IN CD_NNP 14_CD expression_NN ._.
        
        
          Chemotaxis_NNP assay_NN
          Cell_NNP migration_NN was_VBD assessed_VBN by_IN a_DT 48_CD -_: well_RB
          micro-chemotaxis_JJ chamber_NN (_( NeuroProbe_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) ._.
          An_DT aliquot_NN of_IN peptide_NN was_VBD placed_VBN in_IN the_DT lower_JJR
          compartment_NN ,_, and_CC a_DT suspension_NN of_IN monocytes_NNS
          (_( 30_CD ,_, 000_CD -_: 35_CD ,_, 000_CD )_) was_VBD placed_VBN in_IN the_DT upper_JJ compartment_NN of_IN
          the_DT well_NN ._. The_DT two_CD compartments_NNS were_VBD separated_VBN by_IN a_DT
          polyvinylpyrrolidone-free_JJ polycarbonate_NN filter_NN with_IN a_DT
          pore_NN size_NN of_IN 5_CD μm_NN ._. The_DT chamber_NN was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN
          90_CD minutes_NNS ._. At_IN the_DT end_NN of_IN the_DT incubation_NN period_NN the_DT
          filter_NN was_VBD removed_VBN ,_, fixed_VBN ,_, and_CC stained_JJ with_IN a_DT Hema_NNP 3_CD
          stain_VB set_VBN (_( Fisher_NNP ,_, Pittsburgh_NNP ,_, PA_NNP )_) ._. The_DT cells_NNS that_IN
          migrated_JJ through_IN the_DT membrane_NN pore_NN in_IN three_CD high-power_JJ
          fields_NNS (_( ×_NN 400_CD )_) were_VBD counted_VBN by_IN light_JJ microscopy_NN ._. Three_CD
          chamber_NN membranes_NNS were_VBD counted_VBN for_IN each_DT
          concentration_NN ._.
        
        
          Assessment_NNP of_IN mactinin_NN concentrations_NNS necessary_JJ for_IN
          HL-_NNP 60_CD cell_NN maturation_NN
          HL-_NNP 60_CD myeloid_NN leukemia_NN cells_NNS were_VBD seeded_VBN at_IN a_DT density_NN
          of_IN 10_CD 5_CD /_NN ml_NN and_CC grown_VBN for_IN 3_CD days_NNS in_IN RPMI_NNP medium_NN with_IN 50_CD
          μg_NN /_NN ml_NN gentamicin_NN and_CC 15_CD %_NN fetal_JJ calf_NN serum_NN at_IN 37_CD °_NN C_NNP and_CC 5_CD %_NN
          CO_NNP 
          2_CD ,_, in_IN the_DT presence_NN of_IN various_JJ
          concentrations_NNS of_IN recombinant_JJ mactinin_NN ._. We_PRP have_VBP
          previously_RB reported_VBN that_DT mactinin_NN promotes_VBZ monocyte_NN
          maturation_NN as_IN measured_VBN by_IN morphology_NN ,_, non-specific_JJ
          esterase_NN activity_NN ,_, and_CC Fc_NNP rosette_NN formation_NN in_IN this_DT
          leukemia_NN cell_NN line_NN [_NN 7_CD ]_NN ._. Here_RB we_PRP report_VBP the_DT
          concentrations_NNS necessary_JJ to_TO induce_VB maturation_NN as_IN measured_VBN
          by_IN non-specific_JJ esterase_NN staining_VBG used_VBN as_IN a_DT maturation_NN
          marker_NN ._.
        
        
          Antisera_NNP generation_NN
          To_TO generate_VB antisera_NN with_IN sensitivity_NN for_IN detecting_VBG
          mactinin_NN ,_, purified_JJ recombinant_JJ chicken_NN α-actinin_JJ peptide_NN
          was_VBD modified_VBN by_IN coupling_NN with_IN dinitrophenol_NN [_NN 17_CD ]_NN and_CC
          injected_VBN into_IN two_CD New_NNP Zealand_NNP white_JJ rabbits_NNS along_IN with_IN
          complete_JJ Freund_NNP 's_POS adjuvant_NN ,_, as_IN described_VBN previously_RB [_NN 6_CD ]_NN
          ._. Boosts_NNP were_VBD done_VBN with_IN peptide_NN and_CC incomplete_JJ Freund_NNP 's_POS
          adjuvant_NN ._. These_DT animal_NN studies_NNS were_VBD approved_VBN by_IN the_DT
          Institutional_NNP Animal_NNP Care_NNP and_CC Use_NNP Committee_NNP (_( IACUC_NNP )_) of_IN
          the_DT Minneapolis_NNP Veterans_NNP Affairs_NNPS Medical_NNP Center_NNP ._. Antisera_NNP
          were_VBD screened_VBD for_IN their_PRP$ ability_NN to_TO detect_VB the_DT immunizing_VBG
          peptide_NN and_CC were_VBD immunoaffinity-purified_JJ with_IN columns_NNS of_IN
          the_DT recombinant_JJ fragment_NN covalently_RB bound_VBN to_TO a_DT Affi-_NNP Gel_NNP
          15_CD matrix_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ._. We_PRP expected_VBD
          cross-reactivity_JJ of_IN the_DT purified_JJ antisera_NN with_IN fragments_NNS
          from_IN rats_NNS ,_, mice_NNS ,_, or_CC humans_NNS because_IN of_IN the_DT highly_RB
          conserved_JJ amino_JJ acid_NN sequence_NN ._.
        
        
          Synovial_NNP fluid_JJ samples_NNS
          Fluid_NNP from_IN patients_NNS with_IN arthritis_NN undergoing_VBG
          therapeutic_JJ arthrocentesis_NNS was_VBD collected_VBN and_CC tested_VBN for_IN
          the_DT presence_NN of_IN the_DT fragment_NN by_IN Western_JJ blot_NN analysis_NN ._.
          The_DT use_NN of_IN these_DT fluid_JJ samples_NNS in_IN this_DT study_NN was_VBD approved_VBN
          by_IN the_DT subcommittee_NN on_IN human_JJ studies_NNS of_IN the_DT Minneapolis_NNP
          VAMC_NNP ._. In_IN brief_JJ ,_, fresh_JJ samples_NNS were_VBD centrifuged_JJ at_IN 895_CD 
          g_SYM for_IN 10_CD minutes_NNS and_CC frozen_VBN at_IN
          -_: 80_CD °_NN C_NNP until_IN the_DT time_NN of_IN analysis_NN ._. Because_IN mactinin_NN is_VBZ a_DT
          very_RB small_JJ fraction_NN of_IN the_DT total_JJ protein_NN content_NN (_( more_JJR
          than_IN 50_CD μg_NN /_NN 10_CD μl_NN )_) of_IN the_DT fluid_NN ,_, immunoaffinity_NN
          purification_NN of_IN mactinin_NN was_VBD performed_VBN before_IN Western_NNP
          blotting_VBG ._. Samples_NNP were_VBD thawed_JJ ,_, dialyzed_JJ against_IN
          phosphate-buffered_JJ saline_NN ,_, and_CC centrifuged_JJ again_RB ;_: the_DT
          total_JJ sample_NN volume_NN was_VBD then_RB applied_VBN to_TO a_DT column_NN of_IN
          immunoaffinity-purified_JJ antibody_NN covalently_RB bound_VBN to_TO a_DT
          Affi-_NNP Gel_NNP 15_CD matrix_NN ,_, and_CC eluted_JJ with_IN 0_CD ._. 1_CD M_NNP sodium_NN citrate_NN
          in_IN 0_CD ._. 3_CD M_NNP NaCl_NNP ,_, pH_NN 3_CD ._. 0_CD ._. Fractions_NNP (_( 2_CD ml_NN )_) were_VBD collected_VBN
          and_CC neutralized_VBN with_IN 2_CD M_NNP Tris-_NNP HCl_NNP ._. Protein-containing_NNP
          fractions_NNS were_VBD pooled_VBN ,_, dialyzed_JJ against_IN
          phosphate-buffered_JJ saline_NN ,_, concentrated_VBN ,_, and_CC subjected_VBN to_TO
          electrophoresis_NNS on_IN a_DT 12_CD %_NN SDS-PAGE_NNP gel_NN under_IN reducing_VBG
          conditions_NNS ._. Each_DT lane_NN contained_VBD 100_CD μl_NN ,_, representing_VBG
          about_IN 1_CD %_NN of_IN the_DT total_JJ sample_NN ._.
        
        
          Immunoblot_NNP analysis_NN
          The_DT proteins_NNS separated_VBN by_IN SDS-PAGE_NNP were_VBD transferred_VBN
          electrophoretically_RB to_TO poly_RB (_( vinylidene_NN difluoride_NN )_)
          membranes_NNS (_( Bio-_NNP Rad_NNP )_) ._. The_DT membrane_NN was_VBD blocked_VBN with_IN 5_CD %_NN
          nonfat_JJ milk_NN in_IN 50_CD M_NNP Tris-_NNP HCl_NNP /_NN 150_CD M_NNP NaCl_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, and_CC
          sequentially_RB treated_VBN with_IN affinity-purified_JJ rabbit_NN
          antisera_NN raised_VBD against_IN recombinant_JJ mactinin_NN ,_, followed_VBN by_IN
          second_JJ antibody_NN conjugated_JJ with_IN alkaline_NN phosphatase_NN
          (_( ICN_NNP ,_, Costa_NNP Mesa_NNP ,_, CA_NNP )_) ._. Immunoreactive_NNP proteins_NNS were_VBD
          detected_VBN by_IN alkaline_NN phosphatase_NN reaction_NN with_IN
          5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indoyl_NN phosphate_NN /_NN nitroblue_NN
          tetrazolium_NN ._. Control_NN analyses_NNS were_VBD performed_VBN with_IN rabbit_NN
          IgG_NNP (_( Santa_NNP Cruz_NNP Biochemistry_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._.
        
        
          Dissociation_NNP of_IN immune_JJ complexes_NNS in_IN rheumatoid_NN
          arthritis_NN fluid_JJ
          To_TO examine_VB whether_IN mactinin_NN was_VBD present_JJ in_IN immune_JJ
          complexes_NNS in_IN rheumatoid_NN arthritis_NN fluid_JJ ,_, some_DT samples_NNS
          were_VBD acidified_VBN by_IN dialysis_NN against_IN 0_CD ._. 1_CD M_NNP sodium_NN acetate_NN ,_,
          pH_NN 4_CD ._. 1_CD ,_, to_TO dissociate_VB complexes_NNS [_NN 18_CD ]_NN ._. The_DT acidified_VBN
          samples_NNS were_VBD first_JJ fractionated_JJ on_IN an_DT 800_CD ml_NN G-_NNP 75_CD
          Sephadex_NNP (_( Pharmacia_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) size-exclusion_JJ
          column_NN ._. Fractions_NNP identified_VBN by_IN Western_NNP blotting_VBG as_IN
          containing_VBG mactinin_NN were_VBD pooled_VBN ,_, neutralized_VBN ,_, and_CC further_JJ
          purified_JJ by_IN fractionation_NN on_IN a_DT C-_NNP 4_CD column_NN ._. The_DT C-_NNP 4_CD column_NN
          was_VBD equilibrated_JJ with_IN 0_CD ._. 1_CD %_NN trifluoroacetic_JJ acid_NN and_CC
          eluted_JJ with_IN an_DT acetonitrile_NN gradient_NN (_( 0_CD -_: 100_CD %_NN )_) run_VB at_IN
          1_CD %_NN /_NN ml_NN /_NN min_NN ._. Aliquots_NNP of_IN protein-containing_JJ fractions_NNS were_VBD
          used_VBN for_IN Western_JJ blots_NNS ._.
        
        
          Measurement_NNP of_IN mactinin_NN in_IN the_DT antigen-induced_JJ
          arthritis_NN model_NN
          To_TO produce_VB antigen-induced_JJ arthritis_NN ,_, New_NNP Zealand_NNP
          white_JJ rabbits_NNS were_VBD immunized_JJ by_IN subdermal_NN injection_NN of_IN
          ovalbumin_NN emulsified_JJ in_IN complete_JJ Freund_NNP 's_POS adjuvant_NN in_IN
          accordance_NN with_IN modifications_NNS [_NN 14_CD ]_NN of_IN the_DT method_NN of_IN
          Dumonde_NNP and_CC Glynn_NNP [_NN 13_CD ]_NN under_IN IACUC_NNP approval_NN ._. Three_CD
          weeks_NNS later_RB ,_, animals_NNS with_IN positive_JJ skin_NN tests_NNS to_TO
          ovalbumin_NN received_VBD intra-articular_JJ injections_NNS of_IN 1_CD mg_NN of_IN
          sterile_JJ ovalbumin_NN into_IN one_CD knee_NN and_CC an_DT equal_JJ volume_NN of_IN
          sterile_JJ saline_NN in_IN the_DT contralateral_NN control_NN knee_NN weekly_JJ
          for_IN 3_CD weeks_NNS ._. Arthritic_NNP and_CC control_NN knee_NN joints_NNS were_VBD then_RB
          lavaged_JJ with_IN saline_NN and_CC aspirated_JJ at_IN the_DT time_NN of_IN killing_VBG ,_,
          when_WRB animals_NNS had_VBD developed_VBN chronic_JJ synovitis_NNS 10_CD weeks_NNS
          after_IN the_DT intraarticular_NN injections_NNS were_VBD complete_JJ ._.
          Samples_NNP were_VBD frozen_VBN at_IN -_: 80_CD °_NN C_NNP until_IN the_DT time_NN of_IN analysis_NN ._.
          Samples_NNP were_VBD then_RB concentrated_VBN and_CC used_VBN for_IN Western_JJ
          blots_NNS ._.
        
      
      
        Results_NNS
        
          Mactinin_NNP is_VBZ a_DT chemoattractant_NN for_IN peripheral_JJ blood_NN
          monocytes_NNS
          For_IN analysis_NN of_IN the_DT effect_NN of_IN mactinin_NN on_IN monocyte_NN
          chemotaxis_NNS ,_, peripheral_JJ blood_NN monocytes_NNS were_VBD placed_VBN in_IN the_DT
          upper_JJ chambers_NNS of_IN a_DT 48_CD -_: well_RB micro-chamber_JJ plate_NN with_IN
          various_JJ concentrations_NNS of_IN mactinin_NN ._. The_DT lower_JJR compartment_NN
          of_IN the_DT wells_NNS also_RB contained_VBD various_JJ concentrations_NNS of_IN
          mactinin_NN and_CC was_VBD separated_JJ from_IN the_DT upper_JJ chamber_NN by_IN a_DT
          polycarbonate_NN filter_NN ._. As_IN shown_VBN in_IN Table_NNP 1_CD ,_, 1_CD -_: 10_CD nM_NN
          mactinin_NN had_VBD significant_JJ chemotactic_JJ activity_NN for_IN
          monocytes_NNS ._. Intact_NNP α-actinin_JJ at_IN 10_CD nM_NN had_VBD no_DT activity_NN ._.
          Because_IN our_PRP$ mactinin_NN preparations_NNS were_VBD contaminated_VBN with_IN
          up_IN to_TO 10_CD %_NN GST_NNP (_( thus_RB containing_VBG 0_CD ._. 1_CD nM_NN GST_NNP in_IN 1_CD nM_NN
          mactinin_NN )_) ,_, we_PRP tested_VBD 0_CD ._. 1_CD nM_NN GST_NNP alone_RB and_CC also_RB found_VBD no_DT
          activity_NN ._. The_DT number_NN of_IN concentrations_NNS tested_VBN per_IN assay_NN
          was_VBD limited_VBN by_IN the_DT 48_CD wells_NNS (_( 16_CD combinations_NNS for_IN
          triplicate_NN wells_NNS )_) ,_, but_CC in_IN separate_JJ assays_NNS we_PRP have_VBP seen_VBN
          significant_JJ chemotactic_JJ activity_NN at_IN mactinin_NN
          concentrations_NNS as_RB low_JJ as_IN 0_CD ._. 5_CD nM_NN ._. The_DT concentration_NN of_IN
          mactinin_NN necessary_JJ for_IN activity_NN is_VBZ similar_JJ to_TO that_DT of_IN
          FMLP_NNP (_( 0_CD ._. 1_LS -_: 10_CD nM_NN )_) in_IN our_PRP$ assay_NN system_NN ,_, and_CC mactinin_NN and_CC
          FMLP_NNP attract_VBP similar_JJ numbers_NNS of_IN monocytes_NNS ._.
        
        
          Measurement_NNP of_IN mactinin_NN 's_POS maturation-promoting_JJ
          activity_NN
          Recombinant_NNP mactinin_NN has_VBZ maturation-promoting_JJ activity_NN
          
          in_IN vitro_NN in_IN HL-_NNP 60_CD leukemia_NN cells_NNS at_IN
          the_DT concentrations_NNS shown_VBN in_IN Figure_NN 1_CD ._. That_DT is_VBZ ,_, it_PRP induces_VBZ
          non-specific_JJ esterase_NN staining_VBG at_IN 2_CD ._. 5_CD pM_NN and_CC activity_NN
          reaches_VBZ a_DT plateau_NN at_IN 25_CD pM_NN (_( 0_CD ._. 8_CD ng_NN /_NN ml_NN )_) ._. GST_NNP controls_NNS were_VBD
          run_VBN at_IN a_DT similar_JJ range_NN of_IN concentrations_NNS and_CC showed_VBD no_DT
          significant_JJ activity_NN ._.
        
        
          Detection_NNP of_IN mactinin_NN in_IN arthritis_NN fluid_JJ
          Affinity-purified_NNP rabbit_NN antiserum_NN raised_VBD against_IN a_DT
          recombinant_JJ chicken_NN α-actinin_JJ fragment_NN detected_VBD picogram_NN
          amounts_NNS of_IN the_DT immunizing_VBG amino-terminal_JJ protein_NN fragment_NN
          (_( Fig_NNP ._. 2_LS )_) ._. As_IN also_RB shown_VBN in_IN Figure_NN 2_CD ,_, this_DT antiserum_NN
          reacted_VBD with_IN a_DT protein_NN of_IN the_DT expected_VBN molecular_JJ mass_NN in_IN
          representative_NN samples_NNS of_IN immunoaffinity-purified_JJ
          synovial_NN fluid_JJ from_IN patients_NNS with_IN psoriatic_JJ arthritis_NN ,_,
          reactive_JJ arthritis_NN ,_, gout_NN ,_, and_CC ankylosing_VBG spondylitis_NNS ._. In_IN
          all_DT ,_, six_CD of_IN seven_CD samples_NNS from_IN patients_NNS with_IN these_DT
          arthritides_NNS contained_VBD mactinin_NN ._. In_IN contrast_NN ,_, mactinin_NN was_VBD
          detected_VBN in_IN none_NN of_IN five_CD rheumatoid_NN arthritis_NN samples_NNS (_( 
          P_NN <_NN 0_CD ._. 05_CD ;_: Fisher_NNP 's_POS exact_JJ test_NN )_) ._.
          When_WRB the_DT detected_VBD levels_NNS of_IN mactinin_NN are_VBP corrected_VBN for_IN
          the_DT recovery_NN rate_NN by_IN the_DT isolation_NN procedure_NN ,_, they_PRP are_VBP
          1_CD ._. 7_CD -_: 15_CD ng_NN /_NN ml_NN ,_, and_CC are_VBP in_IN the_DT range_NN of_IN
          maturation-promoting_JJ activity_NN 
          in_IN vitro_NN (_( ≥_NN 25_CD pM_NN or_CC 0_CD ._. 8_CD ng_NN /_NN ml_NN )_) and_CC
          the_DT level_NN needed_VBN for_IN chemotactic_JJ activity_NN (_( 0_CD ._. 5_LS nM_NN or_CC 15_CD
          ng_NN /_NN ml_NN )_) ._. The_DT lack_NN of_IN mactinin_NN in_IN rheumatoid_NN arthritis_NN
          fluid_NN was_VBD surprising_JJ ,_, and_CC we_PRP decided_VBD to_TO pursue_VB this_DT
          further_RB ._.
          Owing_NNP to_TO the_DT autoimmune_JJ nature_NN of_IN rheumatoid_NN
          arthritis_NN ,_, we_PRP examined_VBD whether_IN mactinin_NN was_VBD present_JJ in_IN
          immune_JJ complexes_NNS ._. That_DT is_VBZ ,_, antibody-bound_JJ mactinin_NN might_MD
          not_RB bind_NN to_TO the_DT antibody-matrix_JJ column_NN used_VBN in_IN the_DT
          isolation_NN protocol_NN to_TO decrease_VB the_DT total_JJ protein_NN load_NN ,_,
          resulting_VBG in_IN mactinin_NN being_VBG undetectable_JJ but_CC potentially_RB
          active_JJ ._. To_TO dissociate_VB immune_JJ complexes_NNS ,_, an_DT aliquot_NN of_IN a_DT
          rheumatoid_NN arthritis_NN fluid_JJ sample_NN was_VBD acidified_VBN and_CC the_DT
          proteins_NNS were_VBD fractionated_JJ on_IN a_DT C-_NNP 4_CD column_NN ._. As_IN shown_VBN in_IN
          Figure_NN 3_CD ,_, mactinin_NN is_VBZ detectable_JJ by_IN Western_JJ blot_NN analysis_NN
          after_IN dissociation_NN from_IN immune_JJ complexes_NNS ._.
          To_TO confirm_VB the_DT presence_NN of_IN mactinin_NN in_IN rheumatoid_NN
          arthritis_NN fluids_NNS ,_, some_DT frozen_VBN aliquots_NNS were_VBD thawed_JJ and_CC
          immediately_RB subjected_VBN to_TO electrophoresis_NNS on_IN a_DT 12_CD %_NN
          SDS-PAGE_NNP gel_NN under_IN reducing_VBG conditions_NNS ._. As_IN shown_VBN in_IN
          Figure_NN 4_CD ,_, affinity-purified_JJ mactinin_NN antisera_NN reacted_VBD
          with_IN several_JJ 30_CD -_: 40_CD kDa_NN proteins_NNS ,_, including_VBG 31_CD kDa_NN
          mactinin_NN in_IN each_DT of_IN the_DT samples_NNS tested_VBN ._. We_PRP have_VBP
          previously_RB demonstrated_VBN that_IN only_RB the_DT 31_CD kDa_NN α-actinin_JJ
          degradation_NN product_NN has_VBZ maturation-promoting_JJ activity_NN [_NN 5_CD
          ]_NN ._. These_DT proteins_NNS were_VBD not_RB seen_VBN in_IN non-reduced_JJ samples_NNS ,_,
          which_WDT did_VBD have_VB immunoreactive_JJ material_NN at_IN the_DT top_NN of_IN the_DT
          gel_NN (_( data_NNS not_RB shown_VBN )_) ._. Hence_RB ,_, the_DT detected_VBD proteins_NNS might_MD
          represent_VB mactinin_NN bound_VBN to_TO various_JJ immune_JJ complex_JJ
          fragments_NNS ._.
        
        
          Mactinin_NNP is_VBZ present_JJ in_IN inflammatory_JJ fluid_NN from_IN
          antigen-induced_JJ arthritis_NN
          Arthritic_NNP and_CC control_NN knee_NN joints_NNS of_IN rabbits_NNS with_IN
          chronic_JJ antigen-induced_JJ arthritis_NN were_VBD lavaged_JJ with_IN
          saline_NN and_CC aspirated_JJ at_IN the_DT time_NN of_IN killing_VBG ._. Samples_NNP were_VBD
          concentrated_VBN and_CC used_VBN for_IN Western_JJ blots_NNS run_VBP under_IN
          reducing_VBG conditions_NNS ._. As_IN seen_VBN in_IN Figure_NN 5_CD ,_, mactinin_NN is_VBZ
          present_JJ in_IN arthritis_NN joint_JJ fluid_JJ but_CC absent_JJ from_IN control_NN
          fluid_JJ ,_, suggesting_VBG that_DT mactinin_NN formation_NN is_VBZ dependent_JJ on_IN
          the_DT inflammatory_JJ response_NN ._. As_IN also_RB seen_VBN in_IN Figure_NN 5_CD ,_,
          another_DT α-actinin_JJ fragment_NN of_IN slightly_RB higher_JJR molecular_JJ
          mass_NN is_VBZ present_JJ in_IN both_DT samples_NNS ._.
        
      
      
        Discussion_NNP
        During_IN inflammatory_JJ processes_NNS ,_, various_JJ mediators_NNS ,_, such_JJ
        as_IN cytokines_NNS and_CC chemokines_NNS ,_, regulate_VB the_DT recruitment_NN of_IN
        monocytes_NNS ._. Once_RB in_IN the_DT tissue_NN ,_, monocytes_NNS undergo_VBP the_DT poorly_RB
        understood_VBN process_NN of_IN transformation_NN to_TO macrophages_NNS with_IN
        altered_VBN morphology_NN and_CC function_NN [_NN 19_CD ]_NN ._. In_IN arthritis_NN ,_,
        synovial_NN macrophages_NNS might_MD cause_VB joint_JJ destruction_NN by_IN
        differentiating_VBG to_TO bone-resorbing_JJ osteoclasts_NNS [_NN 20_CD ]_NN or_CC by_IN
        releasing_VBG cartilage-degrading_JJ enzymes_NNS and_CC cytokines_NNS ,_, such_JJ
        as_IN interleukin-_NN 1_CD and_CC tumor_NN necrosis_NNS factor-α_JJ [_NN 8_CD ]_NN ._. It_PRP has_VBZ
        therefore_RB been_VBN suggested_VBN that_IN therapies_NNS for_IN chronic_JJ
        arthritis_NN should_MD be_VB aimed_VBN at_IN depleting_VBG joint_JJ mononuclear_NN
        cells_NNS or_CC controlling_VBG the_DT activation_NN of_IN synovial_NN macrophages_NNS
        [_NN 21_CD ]_NN ._. Indeed_RB ,_, elimination_NN of_IN macrophages_NNS by_IN
        clodronate-laden_JJ liposomes_NNS in_IN rat_NN models_NNS of_IN adjuvant_NN [_NN 22_CD ]_NN
        and_CC antigen-induced_JJ arthritis_NN [_NN 23_CD ]_NN induces_VBZ amelioration_NN
        of_IN the_DT arthritis_NN ._.
        Of_IN the_DT many_JJ mediators_NNS of_IN inflammation_NN ,_, mactinin_NN is_VBZ the_DT
        first_JJ example_NN of_IN a_DT fragment_NN of_IN a_DT cytoskeletal_NN component_NN
        that_WDT might_MD be_VB released_VBN during_IN leukocyte_NN influx_NN into_IN
        inflammatory_JJ tissue_NN ._. Further_RB ,_, mactinin_NN might_MD have_VB a_DT role_NN in_IN
        promoting_VBG the_DT response_NN of_IN mononuclear_NN phagocytes_NNS to_TO
        inflammation_NN ._. The_DT monocyte_NN functional_JJ studies_NNS 
        in_IN vitro_NN demonstrate_VB that_IN 0_CD ._. 5_CD -_: 10_CD nM_NN
        levels_NNS of_IN the_DT fragment_NN have_VBP significant_JJ chemotactic_JJ
        activity_NN ._. We_PRP have_VBP previously_RB reported_VBN that_DT mactinin_NN
        promotes_VBZ monocyte_NN maturation_NN ,_, as_IN measured_VBN by_IN lysozyme_NN
        secretion_NN and_CC tartrate-resistant_JJ acid_NN phosphatase_NN staining_VBG
        [_NN 7_CD ]_NN ._. Here_RB we_PRP show_VBP that_IN 25_CD pM_NN levels_NNS of_IN mactinin_NN promote_VB
        monocytic_JJ maturation_NN of_IN the_DT HL-_NNP 60_CD leukemia_NN cell_NN line_NN ._.
        Mactinin_NNP is_VBZ present_JJ at_IN sites_NNS of_IN various_JJ types_NNS of_IN
        arthritic_JJ inflammation_NN at_IN levels_NNS that_WDT are_VBP active_JJ 
        in_IN vitro_NN ,_, including_VBG synovial_NN fluid_JJ
        samples_NNS from_IN patients_NNS with_IN psoriatic_JJ arthritis_NN ,_, reactive_JJ
        arthritis_NN ,_, gout_NN ,_, and_CC ankylosing_VBG spondylitis_NNS ._. Although_IN it_PRP
        was_VBD not_RB initially_RB detected_VBD in_IN five_CD immunoaffinity-purified_JJ
        rheumatoid_NN arthritis_NN samples_NNS ,_, it_PRP was_VBD detected_VBN after_IN the_DT
        acid_NN dissociation_NN of_IN immune_JJ complexes_NNS ._. Girard_NNP and_CC Senecal_NNP [_NN
        24_CD ]_NN have_VBP reported_VBN that_DT sera_NN from_IN patients_NNS with_IN autoimmune_JJ
        diseases_NNS such_JJ as_IN rheumatoid_NN arthritis_NN contain_VB antibodies_NNS
        against_IN microfilament-associated_JJ proteins_NNS ,_, including_VBG
        α-actinin_JJ ._. In_IN addition_NN ,_, auto-antibodies_JJ against_IN actin_NN ,_,
        vinculin_NN ,_, integrins_NNS ,_, or_CC fibronectin_NN could_MD also_RB form_VB
        complexes_NNS with_IN mactinin_NN [_NN 24_CD 25_CD ]_NN ._. Our_PRP$ results_NNS suggest_VBP
        that_DT mactinin_NN is_VBZ bound_VBN to_TO immune_JJ complexes_NNS in_IN rheumatoid_NN
        arthritis_NN joint_JJ fluid_NN ,_, which_WDT prevents_VBZ its_PRP$ binding_JJ to_TO the_DT
        antibody-matrix_JJ during_IN the_DT isolation_NN procedure_NN ._. The_DT finding_VBG
        that_DT mactinin_NN is_VBZ detected_VBN by_IN Western_NNP blotting_VBG of_IN samples_NNS
        run_VBP under_IN reducing_VBG conditions_NNS without_IN immunoaffinity_NN
        purification_NN seems_VBZ to_TO confirm_VB this_DT ._. It_PRP is_VBZ noteworthy_JJ that_IN ,_,
        unless_IN the_DT antibody_NN is_VBZ neutralizing_VBG ,_, even_RB antibody-bound_JJ
        mactinin_NN might_MD still_RB be_VB active_JJ ._.
        The_DT antigen-induced_JJ arthritis_NN model_NN of_IN rheumatoid_NN
        arthritis_NN in_IN rabbits_NNS demonstrates_VBZ persistent_JJ active_JJ
        inflammation_NN for_IN several_JJ months_NNS after_IN the_DT intra-articular_JJ
        injection_NN of_IN antigen_NN ,_, including_VBG hypertrophy_NN and_CC hyperplasia_NN
        of_IN the_DT synovial_NN lining_NN cells_NNS ,_, pannus_JJ formation_NN with_IN
        articular_NN cartilage_NN erosion_NN ,_, and_CC chronic_JJ infiltration_NN of_IN
        synovium_NN by_IN lymphocytes_NNS and_CC plasma_NN cells_NNS [_NN 13_CD ]_NN ._. In_IN
        addition_NN ,_, Dijkstra_NNP and_CC colleagues_NNS [_NN 15_CD ]_NN found_VBD macrophages_NNS
        in_IN the_DT superficial_JJ layer_NN of_IN the_DT synovium_NN ,_, where_WRB they_PRP might_MD
        secrete_NN enzymes_NNS and_CC oxygen_NN radicals_NNS into_IN the_DT joint_JJ space_NN ,_,
        which_WDT can_MD lead_VB to_TO cartilage_NN erosion_NN [_NN 9_CD ]_NN ._. The_DT protein_NN
        levels_NNS in_IN lavage_NN fluid_JJ from_IN arthritic_JJ joints_NNS in_IN this_DT model_NN
        are_VBP low_JJ enough_RB to_TO allow_VB direct_JJ testing_NN by_IN Western_JJ blot_NN
        analysis_NN without_IN immunoaffinity_NN purification_NN ,_, as_IN was_VBD needed_VBN
        with_IN the_DT human_JJ aspirates_NNS ._. Mactinin_NNP was_VBD found_VBN in_IN the_DT lavage_NN
        fluid_JJ from_IN arthritic_JJ knee_NN joints_NNS of_IN rabbits_NNS with_IN this_DT
        immune_JJ arthritis_NN and_CC might_MD contribute_VB to_TO macrophage_NN
        function_NN in_IN this_DT arthritis_NN model_NN ._.
        Because_IN this_DT study_NN was_VBD done_VBN using_VBG waste_NN fluid_JJ from_IN
        therapeutic_JJ synovial_NN fluid_JJ aspirates_NNS ,_, we_PRP did_VBD not_RB have_VB
        samples_NNS from_IN noninflamed_JJ joints_NNS ._. The_DT low_JJ mactinin_NN recovery_NN
        rate_NN during_IN the_DT purification_NN process_NN and_CC the_DT low_JJ
        concentration_NN of_IN mactinin_NN needed_VBN for_IN activity_NN make_NN it_PRP
        necessary_JJ to_TO assay_NN at_IN least_JJS 1_CD ml_NN of_IN fluid_JJ ,_, and_CC this_DT amount_NN
        is_VBZ not_RB available_JJ from_IN any_DT tissue_NN and_CC fluid_JJ bank_NN ._. However_RB ,_,
        mactinin_NN was_VBD not_RB present_JJ in_IN the_DT control_NN joint_JJ fluid_NN in_IN the_DT
        rabbit_NN antigen-induced_JJ arthritis_NN model_NN ,_, suggesting_VBG that_DT
        mactinin_NN is_VBZ specific_JJ for_IN the_DT inflammation_NN process_NN ._.
        Similarly_RB ,_, we_PRP have_VBP reported_VBN that_DT bronchoalveolar_NN lavage_NN
        fluid_JJ from_IN uninfected_JJ mice_NNS contains_VBZ no_DT mactinin_NN ,_, in_IN
        contrast_NN to_TO fluid_JJ from_IN mice_NNS infected_VBN with_IN 
        P_NN ._. carinii_NN [_NN 6_CD ]_NN ._.
        The_DT plasminogen_NN activators_NNS ,_, tissue_NN type_NN and_CC urokinase_NN
        type_NN ,_, have_VBP been_VBN reported_VBN to_TO be_VB both_DT deleterious_JJ in_IN
        inflammation_NN ,_, owing_VBG to_TO the_DT proteolysis_NNS of_IN tissue_NN proteins_NNS ,_,
        and_CC beneficial_JJ because_IN of_IN fibrinolytic_JJ activity_NN [_NN 26_CD ]_NN ._.
        The_DT presence_NN of_IN both_DT increased_VBN urokinase_NN and_CC plasmin_NN
        inhibitors_NNS in_IN rheumatoid_NN arthritis_NN synovial_NN tissue_NN suggests_VBZ
        a_DT complex_JJ role_NN for_IN urokinase_NN in_IN this_DT disease_NN [_NN 27_CD 28_CD 29_CD ]_NN
        that_WDT seems_VBZ pertinent_JJ to_TO our_PRP$ finding_NN of_IN urokinase-generated_JJ
        mactinin_NN in_IN the_DT arthritis_NN fluid_JJ samples_NNS ._. The_DT overall_JJ effect_NN
        of_IN urokinase_NN in_IN the_DT antigen-induced_JJ arthritis_NN model_NN seems_VBZ
        to_TO be_VB beneficial_JJ ,_, because_IN chronic_JJ joint_JJ inflammation_NN and_CC
        bone_NN erosion_NN are_VBP significantly_RB worse_JJR in_IN urokinase-deficient_JJ
        mice_NNS [_NN 30_CD ]_NN ._. However_RB ,_, the_DT ability_NN of_IN urokinase-generated_JJ
        mactinin_NN to_TO enhance_VB proteolysis_NNS might_MD be_VB deleterious_JJ ._.
        Hence_RB ,_, future_JJ testing_NN of_IN specific_JJ mactinin_NN inhibitors_NNS in_IN
        animal_NN models_NNS of_IN arthritis_NN seems_VBZ warranted_VBN ._.
      
      
        Conclusion_NNP
        We_PRP conclude_VBP that_DT mactinin_NN is_VBZ present_JJ in_IN arthritic_JJ
        synovial_NN fluid_JJ in_IN levels_NNS that_WDT can_MD promote_VB mononuclear_NN
        phagocyte_NN chemotaxis_NNS and_CC maturation_NN ._. There_RB ,_, increased_VBN
        numbers_NNS of_IN mature_VBP monocytes_NNS might_MD increase_VB cartilage_NN and_CC
        bone_NN destruction_NN ._. These_DT results_NNS lead_VBP us_PRP to_TO speculate_VB that_IN
        inhibitors_NNS of_IN mactinin_NN might_MD be_VB of_IN benefit_NN in_IN the_DT treatment_NN
        of_IN some_DT forms_NNS of_IN chronic_JJ arthritis_NN and_CC form_VB the_DT basis_NN for_IN
        our_PRP$ plans_NNS to_TO test_VB the_DT efficacy_NN of_IN mactinin_NN antisera_NN to_TO
        ameliorate_NN antigen-induced_JJ arthritis_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        GST_NNP =_SYM glutathione_NN S-_NNP transferase_NN ;_: IACUC_NNP =_SYM Institutional_NNP
        Animal_NNP Care_NNP and_CC Use_NNP Committee_NNP ._.
      
    
  
